Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 590
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Data is available to registered users only
